Mylan Can't Escape Celgene's Suit Over Skin Cancer Patent

Law360 (March 2, 2018, 10:42 PM EST) -- A New Jersey federal judge on Friday refused to dismiss Mylan NV from a suit Celgene Corp. brought against the pharmaceutical company and others to block generic versions of its skin cancer treatment, giving Celgene time to investigate whether Mylan has an established business in the Garden State.

In its motion to dismiss, Mylan and its subsidiaries, Mylan Pharmaceuticals and Mylan Inc., argued that it couldn’t be brought to court in New Jersey for the patent case since, among other requirements, it didn’t have a “regular...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.